Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

A Novel Multipurpose Monoclonal Antibody for Evaluating Human c-Met Expression in Preclinical and Clinical Settings

A Novel Multipurpose Monoclonal Antibody for Evaluating Human c-Met Expression in Preclinical and... RESEARCH ARTICLE A Novel Multipurpose Monoclonal Antibody for Evaluating Human c-Met Expression in Preclinical and Clinical Settings Beatrice S. Knudsen, MD, PhD,*w Ping Zhao,z James Resau, PhD,z Sandra Cottingham, MD,y Ermanno Gherardi, PhD,J Eric Xu, PhD,z Bree Berghuis, BS,z Jennifer Daugherty, BS,z Tessa Grabinski, BS,z Jose Toro, BSc,z Troy Giambernardi, PhD,z R. Scot Skinner, PhD,z Milton Gross, MD,z Eric Hudson, BS,z Eric Kort, MD,z Ernst Lengyel, MD, PhD,# Aviva Ventura, BA,* Richard A. West, MS,z Qian Xie, MD, PhD,z Rick Hay, MD, PhD,z George Vande Woude, PhD,z and Brian Cao, MDz bound c-MET on the surfaces of cultured human cancer cells Abstract: The inappropriate expression of the c-MET cell and tumor xenografts. In summary, the MET4 mAb accurately surface receptor in many human solid tumors necessitates the and reproducibly measures c-MET expression by IHC in FFPE development of companion diagnostics to identify those patients tissues and can be used for molecular imaging in vivo. These who could benefit from c-MET targeted therapies. Tumor properties encourage further development of MET4 as a tissues are formalin fixed and paraffin embedded (FFPE) multipurpose molecular diagnostics reagent to help to guide for histopathologic evaluation, making the development of an appropriate selection of patients http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Applied Immunohistochemistry & Molecular Morphology Wolters Kluwer Health

A Novel Multipurpose Monoclonal Antibody for Evaluating Human c-Met Expression in Preclinical and Clinical Settings

Loading next page...
 
/lp/wolters-kluwer-health/a-novel-multipurpose-monoclonal-antibody-for-evaluating-human-c-met-0WYWg0VoyC
ISSN
1541-2016
DOI
10.1097/PAI.0b013e3181816ae2
pmid
18815565
Publisher site
See Article on Publisher Site

Abstract

RESEARCH ARTICLE A Novel Multipurpose Monoclonal Antibody for Evaluating Human c-Met Expression in Preclinical and Clinical Settings Beatrice S. Knudsen, MD, PhD,*w Ping Zhao,z James Resau, PhD,z Sandra Cottingham, MD,y Ermanno Gherardi, PhD,J Eric Xu, PhD,z Bree Berghuis, BS,z Jennifer Daugherty, BS,z Tessa Grabinski, BS,z Jose Toro, BSc,z Troy Giambernardi, PhD,z R. Scot Skinner, PhD,z Milton Gross, MD,z Eric Hudson, BS,z Eric Kort, MD,z Ernst Lengyel, MD, PhD,# Aviva Ventura, BA,* Richard A. West, MS,z Qian Xie, MD, PhD,z Rick Hay, MD, PhD,z George Vande Woude, PhD,z and Brian Cao, MDz bound c-MET on the surfaces of cultured human cancer cells Abstract: The inappropriate expression of the c-MET cell and tumor xenografts. In summary, the MET4 mAb accurately surface receptor in many human solid tumors necessitates the and reproducibly measures c-MET expression by IHC in FFPE development of companion diagnostics to identify those patients tissues and can be used for molecular imaging in vivo. These who could benefit from c-MET targeted therapies. Tumor properties encourage further development of MET4 as a tissues are formalin fixed and paraffin embedded (FFPE) multipurpose molecular diagnostics reagent to help to guide for histopathologic evaluation, making the development of an appropriate selection of patients

Journal

Applied Immunohistochemistry & Molecular MorphologyWolters Kluwer Health

Published: Jan 1, 2009

There are no references for this article.